Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corp (BCPC) delivers specialty performance ingredients for nutrition and industrial markets through advanced technologies. This news hub provides investors and industry professionals with essential updates on corporate developments and market leadership.
Access authoritative reporting on earnings announcements, product innovations, and strategic partnerships. Our curated collection ensures you stay informed about BCPC's advancements in microencapsulation techniques and chelation technology across human/animal nutrition sectors.
Discover press releases detailing regulatory milestones, manufacturing expansions, and sustainability initiatives. All content is verified for accuracy, offering neutral analysis without speculative commentary.
Bookmark this page for real-time access to Balchem's financial disclosures and operational updates. Regularly refreshed content supports informed decision-making for stakeholders tracking specialty chemical markets.
Balchem Corporation (NASDAQ: BCPC) reported impressive fourth quarter financial results for 2022, with net sales of $232.5 million, up 9.1% from $213.1 million in Q4 2021. However, net earnings decreased to $21.4 million from $24.9 million, although adjusted net earnings rose to $30.3 million from $27.8 million. For the full year, net sales increased 17.9% to a record $942.4 million, while net earnings rose 9.6% to $105.4 million. The company achieved record sales across all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Balchem also maintained a strong cash flow and continues to focus on strategic growth initiatives.
Balchem Corporation (NASDAQ: BCPC) will hold a conference call on February 24, 2023, at 11:00 AM ET to discuss its fourth quarter results. These results will be released before the market opens on the same day. The call will be hosted by Ted Harris (CEO) and Martin Bengtsson (CFO). Investors can join by dialing 1-877-407-8289, and the session will be available for replay until March 10, 2023. Balchem specializes in developing and marketing specialty ingredients across Human Nutrition, Animal Nutrition, and Specialty Products sectors, aiming to enhance health and well-being globally.
Balchem Corporation (NASDAQ: BCPC) CFO Martin Bengtsson will present at the CJS Securities 23rd Annual "New Ideas for the New Year" Investor Conference on January 11, 2023, starting at 11:00 AM EST. The presentation will be accessible on Balchem's website post-conference. Balchem specializes in developing and marketing ingredients that enhance health and well-being across various industries, with three main segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ: BCPC) announced a dividend of $0.71 per share on December 5, 2022, marking a 10.9% increase from the previous year. This dividend will be paid on January 20, 2023, to shareholders on record as of December 27, 2022. The announcement signifies the fourteenth consecutive annual dividend increase, highlighting the company's robust financial performance and the Board's confidence in its long-term strategies.
Balchem Corporation (NASDAQ: BCPC) reported a net earnings increase to $25.2 million for Q3 2022, compared to $25.0 million in Q3 2021. Adjusted net earnings rose to $32.4 million, up 8% year-over-year, with adjusted EBITDA at $53.8 million, reflecting an 11.2% increase.
Net sales reached $244.3 million, a 23.4% increase driven by growth in all segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The effective tax rate declined to 18.8%. Cash flows from operations were $41.6 million, with free cash flow at $26.8 million.
Balchem Corporation (NASDAQ: BCPC) will host a conference call on November 4, 2022, at 11:00 AM ET to discuss its third quarter results. The financial results will be released before market opening on the same day. Interested parties can join the call by dialing 1-877-407-8289 or 1-201-689-8341 locally. A replay will be available until November 18, 2022, using conference ID #13733850. Balchem focuses on developing specialty ingredients across three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ:BCPC) has announced its acquisition of Cardinal Associates Inc., known as Bergstrom Nutrition, a leading producer of methylsulfonylmethane (MSM) based in Vancouver, Washington. This strategic purchase enhances Balchem's product portfolio, particularly in joint health, sports nutrition, and beauty sectors. Bergstrom's OptiMSM® is recognized for its quality, holding a U.S. GRAS designation. The integration aims to accelerate growth and expand marketplace opportunities in Balchem's Human Nutrition and Health segment, aligning with its focus on longevity and performance.
Balchem Corporation (NASDAQ: BCPC) reported a strong second quarter for 2022, with net earnings of $29.8 million, up 31% from $22.7 million in Q2 2021. Adjusted net earnings rose to $34.4 million, reflecting a 13.3% increase year-over-year. Record net sales reached $236.7 million, marking a 17.0% growth, driven by Human, Animal, and Specialty Nutrition segments. The company completed the acquisition of Kappa Bioscience, enhancing its portfolio in the nutrition sector. Operational cash flow was robust at $48.2 million.
Balchem Corporation (NASDAQ: BCPC) will hold a conference call on July 29, 2022, at 11:00 AM ET to discuss its second quarter results, which will be published before market opening on the same day. CEO Ted Harris and CFO Martin Bengtsson will lead the call. Participants can access the conference by calling toll-free 1-877-407-8289. A replay will be available from two hours post-conclusion until August 12, 2022, using conference ID #13731403. For more information, visit www.balchem.com.
FAQ
What is the current stock price of Balchem (BCPC)?
What is the market cap of Balchem (BCPC)?
